Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

Mov Disord. 2006 Jan;21(1):115-6. doi: 10.1002/mds.20666.

Abstract

We performed a double-blind randomized placebo-controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Constipation / drug therapy*
  • Double-Blind Method
  • Female
  • Gastrointestinal Agents / administration & dosage*
  • Gastrointestinal Motility / drug effects
  • Humans
  • Indoles / administration & dosage*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Patient Satisfaction
  • Serotonin 5-HT4 Receptor Agonists
  • Serotonin Receptor Agonists / administration & dosage*

Substances

  • Gastrointestinal Agents
  • Indoles
  • Serotonin 5-HT4 Receptor Agonists
  • Serotonin Receptor Agonists
  • tegaserod